logo BDSP

Base documentaire


  1. Safety profile of dirithromycin.

    Article - En anglais

    Dirithromycin is a recently developed oral antibiotic, and has been shown to be effective in the treatment of respiratory tract, skin and soft tissue infections, Dirithromycin is administered once daily which may contribute to patient compliance.

    In this paper we review the data from studies conducted in Europe, USA, Israel and South Africa over a six-year period to assess the safety and efficacy of dirithromycin in the treatment of a variety of acute infectious illnesses, and to compare it with structurally related antibiotics (erythromycin base, roxithromycin, and miocamycin) given orally.

    A total of 7437 patients have been enrolled from a total of 66 studies and trials, 4263 (57.3%) treated with dirithromycin and 3174 (42.7%) treated with a comparator antibiotic.

    Mots-clés Pascal : Erythromycine, Dirithromycine, Antibiotique, Antibactérien, Etats Unis, Amérique du Nord, Amérique, Macrolide, Voie orale, Chimiothérapie, Traitement, Toxicité, Homme, Epidémiologie, Europe, République Sud Africaine, Afrique, Infection, Israël, Asie, Miocamycine

    Mots-clés Pascal anglais : Erythromycin, Antibiotic, Antibacterial agent, United States, North America, America, Macrolide, Oral administration, Chemotherapy, Treatment, Toxicity, Human, Epidemiology, Europe, South Africa, Africa, Infection, Israel, Asia

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 93-0463347

    Code Inist : 002B02S02. Création : 199406.